Selected research
Market Analysis & Forecast
Global HER2 Antibody Market Analysis and Forecast 2026-2032
Market perspective
The global HER2 Antibody market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for HER2 Antibody is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for HER2 Antibody is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for HER2 Antibody is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for HER2 Antibody is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of HER2 Antibody include Novartis AG, Pfizer, InvivoGen, Genentech Inc, Celltrion, Bio-Techne, Biocon Limited and Abnova Corporation, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for HER2 Antibody, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of HER2 Antibody, also provides the revenue of main regions and countries. Of the upcoming market potential for HER2 Antibody, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the HER2 Antibody revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global HER2 Antibody market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for HER2 Antibody revenue, projected growth trends, production technology, application and end-user industry.
HER2 Antibody Segment by Company
Novartis AG
Pfizer
InvivoGen
Genentech Inc
Celltrion
Bio-Techne
Biocon Limited
Abnova Corporation
HER2 Antibody Segment by Type
Ado-trastuzumab Emtansine
Lapatinib
Pertuzumab
Trastuzumab
Everolimus
HER2 Antibody Segment by Application
Hospital
Medical Center
HER2 Antibody Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global HER2 Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of HER2 Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of HER2 Antibody.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of HER2 Antibody in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of HER2 Antibody company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, HER2 Antibody revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Ado-trastuzumab Emtansine
- Lapatinib
- Pertuzumab
- Trastuzumab
- Everolimus
Applications
- Hospital
- Medical Center
Companies covered
- Novartis AG
- Pfizer
- InvivoGen
- Genentech Inc
- Celltrion
- Bio-Techne
- Biocon Limited
- Abnova Corporation
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 HER2 Antibody Market by Type
- 1.2.1 Global HER2 Antibody Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Ado-trastuzumab Emtansine
- 1.2.3 Lapatinib
- 1.2.4 Pertuzumab
- 1.2.5 Trastuzumab
- 1.2.6 Everolimus
- 1.3 HER2 Antibody Market by Application
- 1.3.1 Global HER2 Antibody Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Hospital
- 1.3.3 Medical Center
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 HER2 Antibody Market Dynamics
- 2.1 HER2 Antibody Industry Trends
- 2.2 HER2 Antibody Industry Drivers
- 2.3 HER2 Antibody Industry Opportunities and Challenges
- 2.4 HER2 Antibody Industry Restraints
3 Global Growth Perspective
- 3.1 Global HER2 Antibody Market Perspective (2021-2032)
- 3.2 Global HER2 Antibody Growth Trends by Region
- 3.2.1 Global HER2 Antibody Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global HER2 Antibody Market Size by Region (2021-2026)
- 3.2.3 Global HER2 Antibody Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global HER2 Antibody Revenue by Players
- 4.1.1 Global HER2 Antibody Revenue by Players (2021-2026)
- 4.1.2 Global HER2 Antibody Revenue Market Share by Players (2021-2026)
- 4.1.3 Global HER2 Antibody Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global HER2 Antibody Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global HER2 Antibody Key Players Headquarters & Area Served
- 4.4 Global HER2 Antibody Players, Product Type & Application
- 4.5 Global HER2 Antibody Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global HER2 Antibody Market CR5 and HHI
- 4.6.3 2025 HER2 Antibody Tier 1, Tier 2, and Tier 3
5 HER2 Antibody Market Size by Type
- 5.1 Global HER2 Antibody Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global HER2 Antibody Revenue by Type (2021-2032)
- 5.3 Global HER2 Antibody Revenue Market Share by Type (2021-2032)
6 HER2 Antibody Market Size by Application
- 6.1 Global HER2 Antibody Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global HER2 Antibody Revenue by Application (2021-2032)
- 6.3 Global HER2 Antibody Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 Novartis AG
- 7.1.1 Novartis AG Company Information
- 7.1.2 Novartis AG Business Overview
- 7.1.3 Novartis AG HER2 Antibody Revenue and Gross Margin (2021-2026)
- 7.1.4 Novartis AG HER2 Antibody Product Portfolio
- 7.1.5 Novartis AG Recent Developments
- 7.2 Pfizer
- 7.2.1 Pfizer Company Information
- 7.2.2 Pfizer Business Overview
- 7.2.3 Pfizer HER2 Antibody Revenue and Gross Margin (2021-2026)
- 7.2.4 Pfizer HER2 Antibody Product Portfolio
- 7.2.5 Pfizer Recent Developments
- 7.3 InvivoGen
- 7.3.1 InvivoGen Company Information
- 7.3.2 InvivoGen Business Overview
- 7.3.3 InvivoGen HER2 Antibody Revenue and Gross Margin (2021-2026)
- 7.3.4 InvivoGen HER2 Antibody Product Portfolio
- 7.3.5 InvivoGen Recent Developments
- 7.4 Genentech Inc
- 7.4.1 Genentech Inc Company Information
- 7.4.2 Genentech Inc Business Overview
- 7.4.3 Genentech Inc HER2 Antibody Revenue and Gross Margin (2021-2026)
- 7.4.4 Genentech Inc HER2 Antibody Product Portfolio
- 7.4.5 Genentech Inc Recent Developments
- 7.5 Celltrion
- 7.5.1 Celltrion Company Information
- 7.5.2 Celltrion Business Overview
- 7.5.3 Celltrion HER2 Antibody Revenue and Gross Margin (2021-2026)
- 7.5.4 Celltrion HER2 Antibody Product Portfolio
- 7.5.5 Celltrion Recent Developments
- 7.6 Bio-Techne
- 7.6.1 Bio-Techne Company Information
- 7.6.2 Bio-Techne Business Overview
- 7.6.3 Bio-Techne HER2 Antibody Revenue and Gross Margin (2021-2026)
- 7.6.4 Bio-Techne HER2 Antibody Product Portfolio
- 7.6.5 Bio-Techne Recent Developments
- 7.7 Biocon Limited
- 7.7.1 Biocon Limited Company Information
- 7.7.2 Biocon Limited Business Overview
- 7.7.3 Biocon Limited HER2 Antibody Revenue and Gross Margin (2021-2026)
- 7.7.4 Biocon Limited HER2 Antibody Product Portfolio
- 7.7.5 Biocon Limited Recent Developments
- 7.8 Abnova Corporation
- 7.8.1 Abnova Corporation Company Information
- 7.8.2 Abnova Corporation Business Overview
- 7.8.3 Abnova Corporation HER2 Antibody Revenue and Gross Margin (2021-2026)
- 7.8.4 Abnova Corporation HER2 Antibody Product Portfolio
- 7.8.5 Abnova Corporation Recent Developments
8 North America
- 8.1 North America HER2 Antibody Revenue (2021-2032)
- 8.2 North America HER2 Antibody Revenue by Type (2021-2032)
- 8.2.1 North America HER2 Antibody Revenue by Type (2021-2026)
- 8.2.2 North America HER2 Antibody Revenue by Type (2027-2032)
- 8.3 North America HER2 Antibody Revenue Share by Type (2021-2032)
- 8.4 North America HER2 Antibody Revenue by Application (2021-2032)
- 8.4.1 North America HER2 Antibody Revenue by Application (2021-2026)
- 8.4.2 North America HER2 Antibody Revenue by Application (2027-2032)
- 8.5 North America HER2 Antibody Revenue Share by Application (2021-2032)
- 8.6 North America HER2 Antibody Revenue by Country
- 8.6.1 North America HER2 Antibody Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America HER2 Antibody Revenue by Country (2021-2026)
- 8.6.3 North America HER2 Antibody Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
- 8.6.6 Mexico
9 Europe
- 9.1 Europe HER2 Antibody Revenue (2021-2032)
- 9.2 Europe HER2 Antibody Revenue by Type (2021-2032)
- 9.2.1 Europe HER2 Antibody Revenue by Type (2021-2026)
- 9.2.2 Europe HER2 Antibody Revenue by Type (2027-2032)
- 9.3 Europe HER2 Antibody Revenue Share by Type (2021-2032)
- 9.4 Europe HER2 Antibody Revenue by Application (2021-2032)
- 9.4.1 Europe HER2 Antibody Revenue by Application (2021-2026)
- 9.4.2 Europe HER2 Antibody Revenue by Application (2027-2032)
- 9.5 Europe HER2 Antibody Revenue Share by Application (2021-2032)
- 9.6 Europe HER2 Antibody Revenue by Country
- 9.6.1 Europe HER2 Antibody Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe HER2 Antibody Revenue by Country (2021-2026)
- 9.6.3 Europe HER2 Antibody Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Russia
- 9.6.9 Spain
- 9.6.10 Netherlands
- 9.6.11 Switzerland
- 9.6.12 Sweden
- 9.6.13 Poland
10 China
- 10.1 China HER2 Antibody Revenue (2021-2032)
- 10.2 China HER2 Antibody Revenue by Type (2021-2032)
- 10.2.1 China HER2 Antibody Revenue by Type (2021-2026)
- 10.2.2 China HER2 Antibody Revenue by Type (2027-2032)
- 10.3 China HER2 Antibody Revenue Share by Type (2021-2032)
- 10.4 China HER2 Antibody Revenue by Application (2021-2032)
- 10.4.1 China HER2 Antibody Revenue by Application (2021-2026)
- 10.4.2 China HER2 Antibody Revenue by Application (2027-2032)
- 10.5 China HER2 Antibody Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia HER2 Antibody Revenue (2021-2032)
- 11.2 Asia HER2 Antibody Revenue by Type (2021-2032)
- 11.2.1 Asia HER2 Antibody Revenue by Type (2021-2026)
- 11.2.2 Asia HER2 Antibody Revenue by Type (2027-2032)
- 11.3 Asia HER2 Antibody Revenue Share by Type (2021-2032)
- 11.4 Asia HER2 Antibody Revenue by Application (2021-2032)
- 11.4.1 Asia HER2 Antibody Revenue by Application (2021-2026)
- 11.4.2 Asia HER2 Antibody Revenue by Application (2027-2032)
- 11.5 Asia HER2 Antibody Revenue Share by Application (2021-2032)
- 11.6 Asia HER2 Antibody Revenue by Country
- 11.6.1 Asia HER2 Antibody Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia HER2 Antibody Revenue by Country (2021-2026)
- 11.6.3 Asia HER2 Antibody Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA HER2 Antibody Revenue (2021-2032)
- 12.2 SAMEA HER2 Antibody Revenue by Type (2021-2032)
- 12.2.1 SAMEA HER2 Antibody Revenue by Type (2021-2026)
- 12.2.2 SAMEA HER2 Antibody Revenue by Type (2027-2032)
- 12.3 SAMEA HER2 Antibody Revenue Share by Type (2021-2032)
- 12.4 SAMEA HER2 Antibody Revenue by Application (2021-2032)
- 12.4.1 SAMEA HER2 Antibody Revenue by Application (2021-2026)
- 12.4.2 SAMEA HER2 Antibody Revenue by Application (2027-2032)
- 12.5 SAMEA HER2 Antibody Revenue Share by Application (2021-2032)
- 12.6 SAMEA HER2 Antibody Revenue by Country
- 12.6.1 SAMEA HER2 Antibody Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA HER2 Antibody Revenue by Country (2021-2026)
- 12.6.3 SAMEA HER2 Antibody Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst